Study period | |||||
---|---|---|---|---|---|
Screening | Treatment period | Post treatment follow up | |||
Timepoint | −7 to 0 days | Day 0 (baseline) | Week 6 (±4 days) | Week 12 (±4 days) | Week 16 (±4 days) |
Enrolment | |||||
Informed consent | X | ||||
Eligibility screen | X | X | |||
Medical consultation and assessment | X | X | X | X | X |
Medical history | X | ||||
Concomitant medication | X | X | X | X | X |
Intervention | |||||
mXFP/ Placebo and Bilastine | X | X | |||
Outcome Assessment | |||||
Weekly urticaria activity score (UAS7) | X | X | X | X | X |
Urticaria Control Test (UCT) | X | X | X | X | |
Visual Analog Scale of Itch Severity (VAS) | X | X | X | X | |
Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) | X | X | X | X | |
Angioedema Activity Score (AAS) | X | X | X | X | |
Serum levels of IgE | X | X | |||
Gut microbiota | X | X | |||
AE/SAE assessment | X | X | X | ||
Laboratory Assessment | |||||
CBP with differentiation | X | X | |||
Renal and Liver function test | X | X | |||
Thyroid function test (FT3, FT4 and TSH) | X |